Moran Eye Middle, University of Utah, will carry out translational AMD analysis with a focus on therapeutics. Particularly, his research involves RGD-targeted Flt23k-intraceptor nanoparticles for prevention and treatment of spontaneous choroidal neovascularization in a novel transgenic murine model of AMD. Tsang, associate professor of medical ophthalmology at the Harkness Attention Institute at Columbia University INFIRMARY, will examine stem cells in individualized, targeted and predictive medicine for AMD.. AFER congratulates the initial Genentech AMD Fellowship recipients ARVO Foundation for Attention Study congratulates the first AFER/Genentech Age-related macular Degeneration Fellowship recipients – Balamurali K.Related StoriesAlnylam presents positive ongoing stage 2 open-label expansion data for Patisiran and RevusiranFDA accepts Braeburn's resubmission of Probuphine NDA for reviewHutchison MediPharma starts sulfatinib Phase I actually trial in USResults of Procedures ARYx ended the first quarter of 2010 with approximately $6.3 million in cash and cash equivalents. The web loss for the 1st one fourth of 2010 was $6.4 million, or $0.22 per share, in comparison to a net loss of $9.4 million, or $0.36 per share, in the same quarter of 2009. The initial quarter 2010 net loss carries a charge of $1.1 million related to the February restructuring of procedures. Of this amount, approximately $900,000 was paid in cash and $200,000 was paid in ARYx common stock.